← Back to Clinical Trials
Recruiting NCT07252947

NCT07252947 Stress and Anxiety Effects on Valuation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07252947
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Reward Value Level
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2025-12-18
Primary Completion 2028-11-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Socially Evaluated Cold Pressor Task (SECPT)Non-Stressful Control Task

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2025-12-18 with a primary completion date of 2028-11-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand how stress, anxiety, and negative affect change learning and decision-making processes. The primary objective is to assess two forms of decision-making-reward adaptation and emotion prediction errors-differ as a function of stress and anxiety. The secondary objectives are to assess how individual differences measured in our studies relate to these decision variables.

Eligibility Criteria

Inclusion Criteria: Aims 1-3: To be eligible for participation in this study, an individual must meet all of the following criteria: * 18-65 years of age * Able to speak, read, and write fluently in English * Be willing and able to follow study procedures and provide informed consent. Aim 4: To be eligible for participation in this study, an individual must meet all of the following criteria: * 18-65 years of age * Diagnosis of GAD * Able to speak, read, and write fluently in English * Be willing and able to follow study procedures and provide informed consent. Exclusion Criteria: Aims 1-3: Individuals will be excluded from participation if any of the following criteria are met: * History of or medication for neurologic or psychiatric disease * High-blood pressure or heart condition * Diabetes, food allergies, metabolic disorders or history of eating disorder * Use of corticosteroids or beta-blockers * Pregnancy Aim 4: Individuals will be excluded from participation if any of the following criteria are met: * High-blood pressure or heart condition * Diabetes, food allergies, metabolic disorders or history of eating disorder * Use of corticosteroids or beta-blockers * Lifetime history of bipolar disorder or any psychotic disorder; substance use disorder in past 3 months; eating disorder in past 6 months; current major depressive disorder (past is allowed) * Active suicidal ideation with plan and intent (indicated by score \>=4 on the Columbia Suicide Severity Scale) * Not on stable dose of psychiatric medication for at least 4 weeks prior to study participation * Pregnancy

Contact & Investigator

Central Contact

Candace Raio, PhD

✉ Candace.Raio@nyulangone.org

📞 212-404-4223

Principal Investigator

Candace Raio, PhD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT07252947 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Reward Value Level. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07252947 currently recruiting?

Yes, NCT07252947 is actively recruiting participants. Contact the research team at Candace.Raio@nyulangone.org for enrollment information.

Where is the NCT07252947 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07252947 clinical trial?

NCT07252947 is sponsored by NYU Langone Health. The principal investigator is Candace Raio, PhD at NYU Langone Health. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology